Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of chronic plaque psoriasis for at least 6 months before the first administration of study drug. Duration since diagnosis may be reported by the participant~* Participant has stable moderate to severe plaque psoriasis (body surface area \[BSA\] \>10, Psoriasis Area and Severity Index \[PASI\] \>10, and Dermatology Quality of Life Index \[DLQI\] \>10) with or without psoriatic arthritis at Baseline~* Must be naïve to and candidate for systemic therapy, as assessed by the investigator~* Participant has an inadequate response, intolerance or contraindication to topical psoriasis treatment~Exclusion Criteria:~* Participants with non-plaque forms of psoriasis~* Participant has previously received systemic therapy for psoriasis, whether biologic or non-biologic or photochemotherapy~* Active systemic infection during the last 2 weeks (exception: common cold) prior to screening.~* Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix~* Participant has any condition or contraindication to Fumaderm that would preclude the patient's participation in the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Risankizumab (Type: EXPERIMENTAL): Participants randomized to receive open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 4, and 16.
- Fumaderm (Type: ACTIVE_COMPARATOR): Participants randomized to receive open-label Fumaderm 30 mg administered as a tablet orally once daily from Week 0 to Week 2 and then up to 240 mg, 3 times daily from Week 3 to Week 24 if 90% Improvement in Psoriasis Area and Severity Index (PASI90) is not achieved and if tolerability allows.

Based on this trial design, predict the completion outcome and termination type (if applicable).